Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 7, 2010, Pages 3575-3582

  Zhang, Rui ^a   He, Rong ^b   Qian, Jiang ^a   Guo, Jie ^a   Xue, Kang ^a   Yuan, Yi Fei ^a  

^a EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; LIPOSOME; RHODAMINE; SODIUM CHLORIDE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELLULAR IMMUNITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG TISSUE LEVEL; ELECTRORETINOGRAPHY; EMULSION; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVAPORATION; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; EYE INFLAMMATION; FEMALE; HISTOLOGY; INFLAMMATION; LEWIS RAT; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE SECTION; UVEORETINITIS; ANIMAL; AUTOIMMUNE DISEASE; CONFOCAL MICROSCOPY; DISEASE MODEL; IMMUNOLOGY; INJECTION; LYMPHOCYTE ACTIVATION; PATHOLOGY; RETINITIS; T LYMPHOCYTE; UVEITIS; VITREOUS BODY;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS; LIPOSOMES; LYMPHOCYTE ACTIVATION; MICROSCOPY, CONFOCAL; RATS; RATS, INBRED LEW; RETINITIS; T-LYMPHOCYTES; TACROLIMUS; UVEITIS, POSTERIOR; VITREOUS BODY;

EID: 77955537470     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4373     Document Type: Article

References (37)

1. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immuno-suppressant isolated from a Streptomyces, I: fermentation, isolation, and physico-chemical and biological characteristics. J Anti-biot. 1987;40:1249-1255.
2. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces, II: immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40:1256-1265.
3. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723-728.
4. Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114:1000-1006.
5. Haupert CL, Jaffe GJ. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin. 2000;40:205-220.
6. Cheng L, Banker AS, Martin M, Kozak I, Freeman WR. Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection. Ophthalmology. 2009;116:1356-1359
7. Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009;19:613-617.
8. Oh-i K, Keino H, Goto H, et al. Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoreti-nitis in Rats. Br J Ophthalmol. 2007;91:237-242.
9. Van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006;14:73-85.
10. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005;50:167-182.
11. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307-318.
12. Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, Takeu-chi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release. 2009; 136:247-253.
13. Camelo S, Lajavardi L, Bochot A, et al. Ocular and systemic bio-distribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. Mol Vis. 2007;13:2263-2274.
14. Abe T, Satoh N, Nakajima A, Koizumi T, Tamada M, Sakuragi S. Characterization of a potent uveitopathogenic site derived from rat phosducin. Exp Eye Res. 1997;65:703-710.
15. Otake K, Shimomura T, Goto T, et al. Preparation of liposomes using an improved supercritical reverse phase evaporation method. Langmuir. 2006;22:2543-2550.
16. Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of reverse-phase evaporation and multilamellar nio-somes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005; 306:71-82.
17. Oh-i K, Keino H, Goto H, et al. Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506). Br J Ophthalmol. 2007;91:1537-1540.
18. Inoki T, Yamagami S, Sakai R, Isobe M, Tsuru T, Kawashima H. Suppression of experimental autoimmune uveoretinitis by anti-a/3 TCR monoclonal antibody. Jpn J Ophthalmol. 2002;46:518-524.
19. Ni YQ, Xu GZ, Hu WZ, Shi L, Qin YW, da CD. Neuroprotective effects of naloxone against light-induced photoreceptor degeneration through inhibiting retinal microglial activation. Invest Ophthalmol Vis Sci. 2008;49:2589-2598.
20. Abrishami M, Ganavati SZ, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina. 2009;29:699-703
21. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci. 2002;43:253-259.
22. Ishikawa T, Hokama H, Katagiri Y, Goto H, Usui M. Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr Eye Res. 2005;30:93-101.
23. Passos E, Genaidy MM, Peyman GA. Ocular toxicity of intravitreal tacrolimus. Ophthalmic Surg Lasers. 2002;33:140-144.
24. Akar Y, Yucel G, Durukan A, Yucel I, Arici G. Systemic toxicity of tacrolimus given by various routes and the response to dose reduction. Clin Exp Ophthalmol. 2005;33:53-59
25. Sakurai E, Nozaki M, Okabe K, Kunou N, Kimura H, Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest Ophthalmol Vis Sci. 2003; 44:4845-4852.
26. Gery I, Wiggert B, Redmond TM, et al. Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-bind-ing protein. Invest Ophthalmol Vis Sci. 1986;27:1296-1300.
27. Sanui H, Redmond TM, Kotake S, et al. Identification of an immu-nodominant and highly immunopathogenic determinant in the retinal interphotoreceptor retinoid-binding protein (IRBP). J Exp Med. 1989;169:1947-1960.
28. Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endo-toxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2007;48:3230-3238.
29. Changsan N, Chan HK, Separovic F, Srichana T. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci. 2009;98:628-639.
30. Arakawa Y, Hashida N, Ohguro N, et al. Eye-concentrated distribution of dexamethasone carried by sugar-chain modified liposome in experimental autoimmune uveoretinitis mice. Biomed Res. 2007;28:331-334.
31. Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des. 2009;15:153-172.
32. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol Appl Pharmacol. 2008;229:121-134.
33. Fenske DB, Cullis PR. Liposomal nanomedicines. Expert Opin Drug Deliv. 2008;5:25-44.
34. Cheng L, Hostetler KY, Chaidhawangul S, et al. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest Ophthalmol Vis Sci. 2000;41:1523-1532.
35. Bochot A, Couvreur P, Fattal E. Intravitreal administration of anti-sense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res. 2000;19:131-147.
36. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;9:1-14.
37. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4:371-388.